| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8443397 | European Journal of Cancer | 2014 | 10 Pages |
Abstract
While KRAS mutation status per se is neither prognostic nor predictive in stage III-IV lung adenocarcinoma, subtype-specific analysis may indeed identify clinically relevant subgroups of patients that may ultimately influence treatment decisions.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Mihaly Cserepes, Gyula Ostoros, Zoltan Lohinai, Erzsebet Raso, Tamas Barbai, Jozsef Timar, Anita Rozsas, Judit Moldvay, Ilona Kovalszky, Katalin Fabian, Marton Gyulai, Bahil Ghanim, Viktoria Laszlo, Thomas Klikovits, Mir Alireza Hoda, Michael Grusch,